EUVIMEDEUVIMED entdecken
Fallbericht

Drug desensitization to lumacaftor/ivacaftor: A fast lane to drug tolerance

J Westhoff, S Barth, L Naehrlich

Journal of Cystic Fibrosis · 2023

DOI: 10.1016/j.jcf.2023.03.015 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Cystic Fibrosis, 2023. Verfasst von J Westhoff und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Pediatric Pulmonology, Justus-Liebig-University Giessen, Germany. Electronic address: julia.westhoff@paediat.med.uni-giesse…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Exanthema. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 6 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We present the case of a girl (now 11 years and 9 months old) with cystic fibrosis (F508del homozygote), who developed pruritic rash and urticaria six days after the first dose of the CFTR modulators lumacaftor/ivacaftor. The treatment was paused and had to be interrupted due to an immediate recurrence of the urticarial rash after rechallenge. We developed a drug desensitization protocol, aligned to protocols used for desensitization against oral antibiotics. In contrast to other published protocols, it was performed by rapidly increasing the dose of lumacaftor/ivacaftor granulate at 15 min intervals. The medication was continued without interruption, the rash did not reappear during follow-up of two years. This drug desensitization protocol provides a potential new therapeutic option for patients with drug hypersensitivity reactions to CFTR modulators, especially when there are no alternative treatments. Lumacaftor/ivacaftor is available as granulate, doses can be titrated during desensitization and used for long-term treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisExanthemaFemaleHumansInfantCystic Fibrosis Transmembrane Conductance RegulatorForced Expiratory VolumeDrug CombinationsAminophenolsAminopyridinesBenzodioxolesDrug ToleranceMutationQuinolones

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorDrug CombinationsAminophenolsAminopyridinesBenzodioxolesivacaftorQuinoloneslumacaftor

Autor:innen und Institutionen

  • Department of Pediatrics, Pediatric Pulmonology, Justus-Liebig-University Giessen, Germany. Electronic address: julia.westhoff@paediat.med.uni-giessen.de.
  • Department of Pediatrics, Pediatric Pulmonology, Justus-Liebig-University Giessen, Germany.

Zitieren

APA

Westhoff, J., Barth, S., & Naehrlich, L. (2023). Drug desensitization to lumacaftor/ivacaftor: A fast lane to drug tolerance. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2023.03.015

Vancouver

Westhoff J, Barth S, Naehrlich L. Drug desensitization to lumacaftor/ivacaftor: A fast lane to drug tolerance. Journal of Cystic Fibrosis. 2023. doi:10.1016/j.jcf.2023.03.015

BibTeX
@article{Westhoff2023,
  author = {Westhoff, J and Barth, S and Naehrlich, L},
  title = {Drug desensitization to lumacaftor/ivacaftor: A fast lane to drug tolerance},
  journal = {Journal of Cystic Fibrosis},
  year = {2023},
  doi = {10.1016/j.jcf.2023.03.015}
}
Kostenlos starten →